Research ExplorerPublicationsSGLT2 Inhibitors and Peripheral Vascular Events: A Review of...

SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature

Standard

SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature. / Marchiori, Elena; Rodionov, Roman N; Peters, Frederik; Magnussen, Christina; Nordanstig, Joakim; Gombert, Alexander; Spanos, Konstantinos; Jarzebska, Natalia; Behrendt, Christian-Alexander.

In: HEART FAIL CLIN, Vol. 18, No. 4, 10.2022, p. 609-623.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Marchiori, E, Rodionov, RN, Peters, F, Magnussen, C, Nordanstig, J, Gombert, A, Spanos, K, Jarzebska, N & Behrendt, C-A 2022, 'SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature', HEART FAIL CLIN, vol. 18, no. 4, pp. 609-623. https://doi.org/10.1016/j.hfc.2022.03.001

APA

Marchiori, E., Rodionov, R. N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., Spanos, K., Jarzebska, N., & Behrendt, C-A. (2022). SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature. HEART FAIL CLIN, 18(4), 609-623. https://doi.org/10.1016/j.hfc.2022.03.001

Vancouver

Marchiori E, Rodionov RN, Peters F, Magnussen C, Nordanstig J, Gombert A et al. SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature. HEART FAIL CLIN. 2022 Oct;18(4):609-623. https://doi.org/10.1016/j.hfc.2022.03.001

Bibtex

@article{4972cc2658974381896240447c17c761,
title = "SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature",
abstract = "Fifty articles comprising 18 randomized controlled trials (RCTs), 16 observational studies, and 16 meta-analyses on the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors were evaluated in the current review. Only one-fourth of the cohorts of recent trials had peripheral arterial disease (PAD), whereas this subgroup was at high risk for amputations. Despite a remarkable heterogeneity of RCTs, only 2 trials on canagliflozin suggested excess amputation rates, whereas several observational studies generated conflicting conclusions and remained short on possible explanations. Preliminary evidence from observational research suggested that patients with PAD may even benefit from SGLT-2 inhibitor treatment due to lower observed heart failure hospitalization rates.",
keywords = "Canagliflozin, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents/pharmacology, Sodium, Sodium-Glucose Transporter 2 Inhibitors/pharmacology",
author = "Elena Marchiori and Rodionov, {Roman N} and Frederik Peters and Christina Magnussen and Joakim Nordanstig and Alexander Gombert and Konstantinos Spanos and Natalia Jarzebska and Christian-Alexander Behrendt",
note = "Copyright {\textcopyright} 2022 Elsevier Inc. All rights reserved.",
year = "2022",
month = oct,
doi = "10.1016/j.hfc.2022.03.001",
language = "English",
volume = "18",
pages = "609--623",
journal = "HEART FAIL CLIN",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature

AU - Marchiori, Elena

AU - Rodionov, Roman N

AU - Peters, Frederik

AU - Magnussen, Christina

AU - Nordanstig, Joakim

AU - Gombert, Alexander

AU - Spanos, Konstantinos

AU - Jarzebska, Natalia

AU - Behrendt, Christian-Alexander

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2022/10

Y1 - 2022/10

N2 - Fifty articles comprising 18 randomized controlled trials (RCTs), 16 observational studies, and 16 meta-analyses on the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors were evaluated in the current review. Only one-fourth of the cohorts of recent trials had peripheral arterial disease (PAD), whereas this subgroup was at high risk for amputations. Despite a remarkable heterogeneity of RCTs, only 2 trials on canagliflozin suggested excess amputation rates, whereas several observational studies generated conflicting conclusions and remained short on possible explanations. Preliminary evidence from observational research suggested that patients with PAD may even benefit from SGLT-2 inhibitor treatment due to lower observed heart failure hospitalization rates.

AB - Fifty articles comprising 18 randomized controlled trials (RCTs), 16 observational studies, and 16 meta-analyses on the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors were evaluated in the current review. Only one-fourth of the cohorts of recent trials had peripheral arterial disease (PAD), whereas this subgroup was at high risk for amputations. Despite a remarkable heterogeneity of RCTs, only 2 trials on canagliflozin suggested excess amputation rates, whereas several observational studies generated conflicting conclusions and remained short on possible explanations. Preliminary evidence from observational research suggested that patients with PAD may even benefit from SGLT-2 inhibitor treatment due to lower observed heart failure hospitalization rates.

KW - Canagliflozin

KW - Diabetes Mellitus, Type 2

KW - Glucose

KW - Humans

KW - Hypoglycemic Agents/pharmacology

KW - Sodium

KW - Sodium-Glucose Transporter 2 Inhibitors/pharmacology

U2 - 10.1016/j.hfc.2022.03.001

DO - 10.1016/j.hfc.2022.03.001

M3 - SCORING: Review article

C2 - 36216490

VL - 18

SP - 609

EP - 623

JO - HEART FAIL CLIN

JF - HEART FAIL CLIN

SN - 1551-7136

IS - 4

ER -